AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
PCM-075 Sensitive: C3 – Early Trials
|
PCM-075 Sensitive: C3 – Early Trials
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
abiraterone acetate + RG7440 Resistant: C3 – Early Trials
|
abiraterone acetate + RG7440 Resistant: C3 – Early Trials
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
enzalutamide capsule Resistant: C3 – Early Trials
|
enzalutamide capsule Resistant: C3 – Early Trials
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
abiraterone acetate Resistant: C3 – Early Trials
|
abiraterone acetate Resistant: C3 – Early Trials
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
ODM-208 Sensitive: C3 – Early Trials
|
ODM-208 Sensitive: C3 – Early Trials
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
CPI-0209 Sensitive: D – Preclinical
|
CPI-0209 Sensitive: D – Preclinical
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
docetaxel Resistant: D – Preclinical
|
docetaxel Resistant: D – Preclinical
|
AR mutation
|
Prostate Cancer
|
AR mutation
|
Prostate Cancer
|
5-fluorouracil Resistant: D – Preclinical
|
5-fluorouracil Resistant: D – Preclinical
|